ArticleBMC cancer2026
Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis independently influences survival outcomes in patients with ovarian cancer and investigated the clinicopathologic characteristics of endometriosis-associated ovarian tumors.
methodsThis retrospective cohort study included patients treated for primary malignant or borderline ovarian tumors between January 2014 and July 2025 at a tertiary ESGO-accredited German academic center. Concurrent endometriosis was defined by histologic confirmation at primary surgery and classified as endometriosis-correlated ovarian tumors when histopathologic a transitional lesion from endometriosis to tumor was identified, or as endometriosis-incidental ovarian tumors when endometriosis was identified without transitional lesions. An age-matched reference cohort without endometriosis (1:5) was used for comparison. Survival analyses were restricted to patients with epithelial ovarian cancer and performed using Kaplan–Meier estimates and multivariable Cox regression, adjusting for age, histologic subtype, FIGO stage, endometriosis status, and surgical outcomes.
resultsAmong 2,164 eligible patients, 176 (8.1%) had histologically confirmed endometriosis, including 22 (1.0%) endometriosis-correlated ovarian tumors and 154 (7.1%) endometriosis-incidental ovarian tumors. Patients with endometriosis were significantly younger and more frequently diagnosed with early-stage disease and endometrioid or clear cell histology compared with patients without endometriosis. Endometriosis-correlated ovarian tumors showed a high prevalence of ovarian endometriosis, the absence of p53 aberrations, and no BRCA1/2 mutations. Median overall survival was not reached for patients with endometriosis-correlated ovarian tumors or endometriosis-incidental ovarian tumors. After multivariable adjustment, neither endometriosis-correlated ovarian tumors nor endometriosis-incidental ovarian tumors was independently associated with overall or disease-free survival. Advanced FIGO stage, older age, and incomplete cytoreduction were independently associated with worse survival.
conclusionsEndometriosis-associated ovarian tumors show favorable clinicopathologic features but concurrent endometriosis is not an independent prognostic factor for survival in patients with ovarian cancer. Prognosis appears to be driven primarily by tumor biology, stage, and surgical outcome rather than the presence of endometriosis itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.